2021
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)
Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech LB, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treatment Reviews 2021, 99: 102241. PMID: 34174668, DOI: 10.1016/j.ctrv.2021.102241.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentTreatment alterationsCIPN severityPeripheral neuropathyPatient factorsChemotherapy treatmentRelative dose intensityClinical Oncology guidelinesNeurotoxic chemotherapyDose intensityProspective trialOncology guidelinesRetrospective analysisAdult cancersIndividual patientsInconsistent recommendationsPatientsTreatment efficacyClinical decisionSeverityNeuropathyAmerican SocietyTreatmentClinicians
2017
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton M, Loprinzi C, Chaudhari A, Lustberg M. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research And Treatment 2017, 164: 69-77. PMID: 28374323, PMCID: PMC5510549, DOI: 10.1007/s10549-017-4230-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPatient-reported outcomesTaxane-based chemotherapyCancer patientsChemotherapy cyclesEarly-stage breast cancer patientsPatient-reported symptom severityDevelopment of CIPNSubsequent chemotherapy cyclesFirst chemotherapy cyclePatient-reported symptomsDose-limiting toxicityOutpatient oncology clinicsSelf-reported symptomsTaxane infusionTaxane therapyTaxane treatmentCIPN symptomsDose intensityPeripheral neuropathyOncology clinicPatient functionPhysical functionFunctional deficitsGait testing